Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model

AIMS: To estimate the potential cost-effectiveness of adalimumab compared with standard care alone for the treatment of early-stage Dupuytren’s disease (DD) and the value of further research from an NHS perspective. METHODS: We used data from the Repurposing anti-TNF for Dupuytren’s disease (RIDD) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakin, Helen, Rombach, Ines, Dritsaki, Melina, Gray, Alastair, Ball, Catherine, Lamb, Sarah E., Nanchahal, Jagdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2022
Materias:
Wrist & Hand
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709491/
https://www.ncbi.nlm.nih.gov/pubmed/36378072
http://dx.doi.org/10.1302/2633-1462.311.BJO-2022-0103.R2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709491/
https://www.ncbi.nlm.nih.gov/pubmed/36378072
http://dx.doi.org/10.1302/2633-1462.311.BJO-2022-0103.R2

Ejemplares similares